Share Price and Basic Stock Data
Last Updated: November 28, 2025, 8:26 am
| PEG Ratio | -29.41 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ipca Laboratories Ltd, a prominent player in the pharmaceuticals sector, reported a market capitalization of ₹36,710 Cr with a current share price at ₹1,447. The company has shown a robust upward trajectory in revenue, with sales rising from ₹5,797 Cr in FY 2022 to ₹6,204 Cr in FY 2023, and anticipated to reach ₹7,662 Cr by FY 2024. This represents a growth rate of approximately 15% year-on-year. The quarterly sales figures further illustrate this growth, with the most recent quarter (Sep 2023) recording sales of ₹2,034 Cr, up from ₹1,512 Cr in Mar 2023. This trend is indicative of strong demand and effective market strategies. The company’s operating profit margin (OPM) stood at 18% for the most recent quarter, reflecting its ability to maintain profitability amidst rising costs. The trailing twelve months (TTM) revenue reached ₹9,357 Cr, underscoring the operational efficiency that the company has achieved over the past year.
Profitability and Efficiency Metrics
Ipca Laboratories reported a net profit of ₹854 Cr, translating to a net profit margin of 8.80% for FY 2025. The profitability indicators suggest a stable income generation capability, with an operating profit margin fluctuating between 12% and 19% over the last few quarters, demonstrating resilience despite varying expense levels. The interest coverage ratio (ICR) was robust at 21.42x, highlighting the company’s strong ability to meet interest obligations. However, the return on equity (ROE) stood at 12.8%, which is on the lower side compared to industry averages, indicating room for improvement in utilizing shareholder equity effectively. The cash conversion cycle (CCC) at 302 days reflects a longer duration for converting investments in inventory and receivables into cash, which may pose liquidity challenges. Overall, while profitability metrics are encouraging, enhancing operational efficiency remains a key focus area for the company.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ipca Laboratories demonstrates a healthy financial structure with total assets amounting to ₹11,744 Cr against total liabilities of ₹11,097 Cr, indicating a solid asset base. The company’s borrowings stood at ₹1,363 Cr, showcasing a manageable debt level with a debt-to-equity ratio of 0.18, well within acceptable limits for the pharmaceuticals sector. Reserves grew to ₹6,923 Cr, providing a cushion for future investments and operational needs. Moreover, the price-to-book value ratio (P/BV) was reported at 5.48x, suggesting that the market values the company at a premium compared to its book value. The current ratio of 2.63x indicates strong short-term liquidity, while the quick ratio of 1.55x suggests that the company can cover its immediate liabilities without relying on inventory sales. Collectively, these ratios reflect a financially sound organization capable of sustaining growth and managing risk effectively.
Shareholding Pattern and Investor Confidence
The shareholding structure of Ipca Laboratories indicates a diversified ownership model, with promoters holding 44.72% of the shares, while domestic institutional investors (DIIs) hold a significant 36.45%. This strong institutional backing reflects confidence in the company’s long-term prospects. Foreign institutional investors (FIIs) own 10.42% of the company, which is consistent with trends seen in other established pharmaceutical firms. The total number of shareholders stood at 82,870, showing a healthy level of public interest in the company’s stock. However, it is noteworthy that promoter holding has seen a slight decline from 46.29% in Dec 2022 to 44.72% in Mar 2025, which could raise questions about long-term commitment. These dynamics highlight a balanced approach to ownership, fostering both stability and growth potential, crucial for attracting further investments.
Outlook, Risks, and Final Insight
Looking ahead, Ipca Laboratories is positioned for continued growth driven by its expanding product portfolio and strong sales performance. However, the company faces risks including fluctuating raw material costs and regulatory challenges inherent in the pharmaceutical sector. Additionally, the increasing cash conversion cycle may impact liquidity if not addressed. Strengths include a solid balance sheet, high interest coverage ratio, and strong institutional support, which can provide stability during market fluctuations. If the company can enhance its operational efficiency and address liquidity concerns, it could unlock significant value for shareholders. Conversely, any adverse regulatory developments or significant cost increases could pose risks to profitability. Overall, the company’s fundamentals are strong, but maintaining focus on efficiency and cost control will be critical for sustaining its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ipca Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 164 Cr. | 130 | 247/84.3 | 36.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,467 Cr. | 410 | 479/192 | 92.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.0 Cr. | 28.0 | 29.3/17.0 | 97.7 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,336.40 Cr | 1,175.88 | 52.22 | 202.44 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,586 | 1,601 | 1,546 | 1,512 | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 |
| Expenses | 1,317 | 1,341 | 1,330 | 1,331 | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 |
| Operating Profit | 269 | 260 | 216 | 181 | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 |
| OPM % | 17% | 16% | 14% | 12% | 19% | 18% | 16% | 16% | 19% | 19% | 21% | 19% | 18% |
| Other Income | 22 | 36 | 31 | 36 | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 |
| Interest | 7 | 9 | 11 | 18 | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 |
| Depreciation | 62 | 64 | 67 | 70 | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 |
| Profit before tax | 223 | 223 | 169 | 129 | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 |
| Tax % | 33% | 35% | 32% | 37% | 34% | 39% | 23% | 96% | 31% | 29% | 25% | 49% | 29% |
| Net Profit | 145 | 146 | 110 | 78 | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 |
| EPS in Rs | 5.64 | 5.67 | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 |
Last Updated: August 20, 2025, 8:55 am
Below is a detailed analysis of the quarterly data for Ipca Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2,309.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,247.00 Cr. (Mar 2025) to 2,309.00 Cr., marking an increase of 62.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,892.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,818.00 Cr. (Mar 2025) to 1,892.00 Cr., marking an increase of 74.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 416.00 Cr.. The value appears to be declining and may need further review. It has decreased from 429.00 Cr. (Mar 2025) to 416.00 Cr., marking a decrease of 13.00 Cr..
- For OPM %, as of Jun 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 19.00% (Mar 2025) to 18.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from -179.00 Cr. (Mar 2025) to 33.00 Cr., marking an increase of 212.00 Cr..
- For Interest, as of Jun 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 100.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 100.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 331.00 Cr.. The value appears strong and on an upward trend. It has increased from 128.00 Cr. (Mar 2025) to 331.00 Cr., marking an increase of 203.00 Cr..
- For Tax %, as of Jun 2025, the value is 29.00%. The value appears to be improving (decreasing) as expected. It has decreased from 49.00% (Mar 2025) to 29.00%, marking a decrease of 20.00%.
- For Net Profit, as of Jun 2025, the value is 233.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 233.00 Cr., marking an increase of 169.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 9.19. The value appears strong and on an upward trend. It has increased from 2.67 (Mar 2025) to 9.19, marking an increase of 6.52.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:07 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,282 | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,357 |
| Expenses | 2,539 | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 7,166 | 7,504 |
| Operating Profit | 743 | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,853 |
| OPM % | 23% | 17% | 10% | 14% | 14% | 19% | 20% | 29% | 23% | 15% | 17% | 19% | 20% |
| Other Income | 21 | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 123 | 17 | -114 | -157 |
| Interest | 30 | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 48 | 141 | 88 | 76 |
| Depreciation | 103 | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 | 357 | 398 | 402 |
| Profit before tax | 631 | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,218 |
| Tax % | 24% | 28% | 18% | 26% | 18% | 19% | 18% | 17% | 20% | 34% | 37% | 30% | |
| Net Profit | 479 | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 854 |
| EPS in Rs | 18.96 | 10.07 | 3.69 | 7.71 | 9.49 | 17.60 | 23.99 | 44.94 | 34.85 | 18.58 | 21.57 | 29.08 | 32.78 |
| Dividend Payout % | 13% | 5% | 0% | 6% | 5% | 9% | 10% | 9% | 11% | 22% | 19% | 14% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -46.97% | -63.39% | 109.68% | 22.56% | 84.94% | 36.65% | 88.91% | -22.00% | -46.18% | 9.19% | 50.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | -16.41% | 173.06% | -87.11% | 62.37% | -48.29% | 52.26% | -110.91% | -24.18% | 55.37% | 40.91% |
Ipca Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 7% |
| 3 Years: | -1% |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 6% |
| 3 Years: | 15% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 14% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 7:50 am
Balance Sheet
Last Updated: July 25, 2025, 2:59 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 1,934 | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,602 | 4,676 | 5,439 | 5,817 | 6,307 | 6,923 |
| Borrowings | 603 | 935 | 867 | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | 1,438 | 1,363 |
| Other Liabilities | 648 | 669 | 765 | 788 | 799 | 961 | 1,130 | 1,099 | 1,349 | 1,300 | 3,326 | 3,432 |
| Total Liabilities | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 |
| Fixed Assets | 1,354 | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,402 | 2,751 | 4,554 | 4,267 |
| CWIP | 165 | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 | 622 |
| Investments | 9 | 16 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 | 980 |
| Other Assets | 1,683 | 1,729 | 1,723 | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,105 | 5,339 | 5,875 |
| Total Assets | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 |
Below is a detailed analysis of the balance sheet data for Ipca Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
- For Reserves, as of Mar 2025, the value is 6,923.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,307.00 Cr. (Mar 2024) to 6,923.00 Cr., marking an increase of 616.00 Cr..
- For Borrowings, as of Mar 2025, the value is 1,363.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,438.00 Cr. (Mar 2024) to 1,363.00 Cr., marking a decrease of 75.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 3,432.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,326.00 Cr. (Mar 2024) to 3,432.00 Cr., marking an increase of 106.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 11,744.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,097.00 Cr. (Mar 2024) to 11,744.00 Cr., marking an increase of 647.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 4,267.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,554.00 Cr. (Mar 2024) to 4,267.00 Cr., marking a decrease of 287.00 Cr..
- For CWIP, as of Mar 2025, the value is 622.00 Cr.. The value appears strong and on an upward trend. It has increased from 343.00 Cr. (Mar 2024) to 622.00 Cr., marking an increase of 279.00 Cr..
- For Investments, as of Mar 2025, the value is 980.00 Cr.. The value appears strong and on an upward trend. It has increased from 862.00 Cr. (Mar 2024) to 980.00 Cr., marking an increase of 118.00 Cr..
- For Other Assets, as of Mar 2025, the value is 5,875.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,339.00 Cr. (Mar 2024) to 5,875.00 Cr., marking an increase of 536.00 Cr..
- For Total Assets, as of Mar 2025, the value is 11,744.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,097.00 Cr. (Mar 2024) to 11,744.00 Cr., marking an increase of 647.00 Cr..
Notably, the Reserves (6,923.00 Cr.) exceed the Borrowings (1,363.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 140.00 | -394.00 | -573.00 | -265.00 | -173.00 | 230.00 | 403.00 | -264.00 | -806.00 | 931.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 41 | 57 | 58 | 67 | 66 | 71 | 55 | 57 | 58 | 80 | 77 |
| Inventory Days | 272 | 293 | 289 | 290 | 286 | 316 | 294 | 337 | 337 | 276 | 350 | 336 |
| Days Payable | 110 | 97 | 145 | 130 | 137 | 154 | 135 | 140 | 101 | 83 | 110 | 111 |
| Cash Conversion Cycle | 213 | 237 | 200 | 218 | 216 | 228 | 229 | 251 | 293 | 251 | 321 | 302 |
| Working Capital Days | 82 | 68 | 61 | 74 | 80 | 88 | 88 | 103 | 102 | 71 | 111 | 101 |
| ROCE % | 28% | 14% | 5% | 9% | 10% | 16% | 19% | 31% | 20% | 11% | 13% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid-Cap Opportunities Fund - Regular Plan | 16,101,893 | 2.58 | 1819.03 | 16,101,893 | 2025-04-22 13:31:13 | 0% |
| Kotak Emerging Equity Fund - Regular Plan | 9,174,301 | 2.11 | 1036.42 | 9,174,301 | 2025-04-22 17:25:30 | 0% |
| DSP Mid Cap Fund | 5,164,736 | 3.05 | 583.46 | 5,164,736 | 2025-04-22 17:25:30 | 0% |
| Parag Parikh Flexi Cap Fund | 3,541,831 | 0.56 | 400.12 | 3,541,831 | 2025-04-22 17:25:30 | 0% |
| Nippon India Growth Fund | 3,100,000 | 1.14 | 350.21 | 3,100,000 | 2025-04-22 17:25:30 | 0% |
| DSP Small Cap Fund | 2,572,727 | 1.91 | 290.64 | 2,572,727 | 2025-04-22 17:25:30 | 0% |
| HDFC Balanced Advantage Fund - Regular Plan | 2,447,056 | 0.31 | 276.44 | 2,447,056 | 2025-04-22 17:25:30 | 0% |
| Kotak Equity Opportunities Fund - Regular Plan | 2,200,000 | 1.03 | 248.53 | 2,200,000 | 2025-04-22 17:25:30 | 0% |
| DSP ELSS Tax Saver Fund | 1,681,026 | 1.17 | 189.91 | 1,681,026 | 2025-04-22 17:25:30 | 0% |
| UTI Flexi Cap Fund | 1,645,559 | 0.72 | 185.9 | 1,645,559 | 2025-04-22 17:25:30 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 |
| Basic EPS (Rs.) | 35.14 | 25.82 | 18.58 | 34.85 | 45.01 |
| Diluted EPS (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 45.01 |
| Cash EPS (Rs.) | 46.72 | 34.94 | 29.70 | 45.07 | 107.06 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Revenue From Operations / Share (Rs.) | 352.37 | 303.71 | 246.13 | 229.79 | 427.28 |
| PBDIT / Share (Rs.) | 71.70 | 56.99 | 41.48 | 54.23 | 126.70 |
| PBIT / Share (Rs.) | 56.02 | 42.91 | 31.17 | 45.07 | 110.21 |
| PBT / Share (Rs.) | 44.59 | 33.22 | 29.38 | 44.77 | 109.50 |
| Net Profit / Share (Rs.) | 31.04 | 20.86 | 19.39 | 35.91 | 90.57 |
| NP After MI And SOA / Share (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 89.87 |
| PBDIT Margin (%) | 20.34 | 18.76 | 16.85 | 23.59 | 29.65 |
| PBIT Margin (%) | 15.89 | 14.12 | 12.66 | 19.61 | 25.79 |
| PBT Margin (%) | 12.65 | 10.93 | 11.93 | 19.48 | 25.62 |
| Net Profit Margin (%) | 8.80 | 6.86 | 7.87 | 15.62 | 21.19 |
| NP After MI And SOA Margin (%) | 8.25 | 7.10 | 7.54 | 15.16 | 21.03 |
| Return on Networth / Equity (%) | 10.61 | 8.64 | 8.06 | 16.09 | 24.24 |
| Return on Capital Employeed (%) | 15.15 | 12.44 | 11.59 | 18.52 | 28.48 |
| Return On Assets (%) | 6.27 | 4.93 | 5.46 | 11.57 | 18.78 |
| Long Term Debt / Equity (X) | 0.07 | 0.09 | 0.11 | 0.07 | 0.00 |
| Total Debt / Equity (X) | 0.18 | 0.21 | 0.24 | 0.14 | 0.05 |
| Asset Turnover Ratio (%) | 0.78 | 0.78 | 0.76 | 0.79 | 0.91 |
| Current Ratio (X) | 2.63 | 2.35 | 2.87 | 3.04 | 2.96 |
| Quick Ratio (X) | 1.55 | 1.30 | 1.91 | 1.77 | 1.59 |
| Inventory Turnover Ratio (X) | 3.55 | 1.05 | 0.94 | 0.95 | 1.10 |
| Dividend Payout Ratio (NP) (%) | 13.75 | 9.27 | 21.53 | 11.47 | 8.90 |
| Dividend Payout Ratio (CP) (%) | 8.93 | 5.60 | 13.84 | 9.08 | 7.52 |
| Earning Retention Ratio (%) | 86.25 | 90.73 | 78.47 | 88.53 | 91.10 |
| Cash Earning Retention Ratio (%) | 91.07 | 94.40 | 86.16 | 90.92 | 92.48 |
| Interest Coverage Ratio (X) | 21.42 | 10.46 | 23.11 | 178.91 | 177.79 |
| Interest Coverage Ratio (Post Tax) (X) | 12.69 | 5.61 | 11.80 | 119.46 | 128.08 |
| Enterprise Value (Cr.) | 40485.27 | 33899.87 | 20234.90 | 27148.88 | 24038.82 |
| EV / Net Operating Revenue (X) | 4.53 | 4.40 | 3.24 | 4.66 | 4.44 |
| EV / EBITDA (X) | 22.26 | 23.45 | 19.23 | 19.73 | 14.96 |
| MarketCap / Net Operating Revenue (X) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
| Retention Ratios (%) | 86.24 | 90.72 | 78.46 | 88.52 | 91.09 |
| Price / BV (X) | 5.48 | 4.96 | 3.52 | 4.90 | 5.13 |
| Price / Net Operating Revenue (X) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 |
After reviewing the key financial ratios for Ipca Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 35.14. This value is within the healthy range. It has increased from 25.82 (Mar 24) to 35.14, marking an increase of 9.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
- For Cash EPS (Rs.), as of Mar 25, the value is 46.72. This value is within the healthy range. It has increased from 34.94 (Mar 24) to 46.72, marking an increase of 11.78.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 352.37. It has increased from 303.71 (Mar 24) to 352.37, marking an increase of 48.66.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 71.70. This value is within the healthy range. It has increased from 56.99 (Mar 24) to 71.70, marking an increase of 14.71.
- For PBIT / Share (Rs.), as of Mar 25, the value is 56.02. This value is within the healthy range. It has increased from 42.91 (Mar 24) to 56.02, marking an increase of 13.11.
- For PBT / Share (Rs.), as of Mar 25, the value is 44.59. This value is within the healthy range. It has increased from 33.22 (Mar 24) to 44.59, marking an increase of 11.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 31.04. This value is within the healthy range. It has increased from 20.86 (Mar 24) to 31.04, marking an increase of 10.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
- For PBDIT Margin (%), as of Mar 25, the value is 20.34. This value is within the healthy range. It has increased from 18.76 (Mar 24) to 20.34, marking an increase of 1.58.
- For PBIT Margin (%), as of Mar 25, the value is 15.89. This value is within the healthy range. It has increased from 14.12 (Mar 24) to 15.89, marking an increase of 1.77.
- For PBT Margin (%), as of Mar 25, the value is 12.65. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 12.65, marking an increase of 1.72.
- For Net Profit Margin (%), as of Mar 25, the value is 8.80. This value is within the healthy range. It has increased from 6.86 (Mar 24) to 8.80, marking an increase of 1.94.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.25. This value is within the healthy range. It has increased from 7.10 (Mar 24) to 8.25, marking an increase of 1.15.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.61. This value is below the healthy minimum of 15. It has increased from 8.64 (Mar 24) to 10.61, marking an increase of 1.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.15. This value is within the healthy range. It has increased from 12.44 (Mar 24) to 15.15, marking an increase of 2.71.
- For Return On Assets (%), as of Mar 25, the value is 6.27. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 6.27, marking an increase of 1.34.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.07, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.18, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.78. There is no change compared to the previous period (Mar 24) which recorded 0.78.
- For Current Ratio (X), as of Mar 25, the value is 2.63. This value is within the healthy range. It has increased from 2.35 (Mar 24) to 2.63, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.55, marking an increase of 0.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 4. It has increased from 1.05 (Mar 24) to 3.55, marking an increase of 2.50.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.75. This value is below the healthy minimum of 20. It has increased from 9.27 (Mar 24) to 13.75, marking an increase of 4.48.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.93. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 24) to 8.93, marking an increase of 3.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 86.25. This value exceeds the healthy maximum of 70. It has decreased from 90.73 (Mar 24) to 86.25, marking a decrease of 4.48.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.07. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 24) to 91.07, marking a decrease of 3.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 21.42. This value is within the healthy range. It has increased from 10.46 (Mar 24) to 21.42, marking an increase of 10.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.69. This value is within the healthy range. It has increased from 5.61 (Mar 24) to 12.69, marking an increase of 7.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 40,485.27. It has increased from 33,899.87 (Mar 24) to 40,485.27, marking an increase of 6,585.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.53. This value exceeds the healthy maximum of 3. It has increased from 4.40 (Mar 24) to 4.53, marking an increase of 0.13.
- For EV / EBITDA (X), as of Mar 25, the value is 22.26. This value exceeds the healthy maximum of 15. It has decreased from 23.45 (Mar 24) to 22.26, marking a decrease of 1.19.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
- For Retention Ratios (%), as of Mar 25, the value is 86.24. This value exceeds the healthy maximum of 70. It has decreased from 90.72 (Mar 24) to 86.24, marking a decrease of 4.48.
- For Price / BV (X), as of Mar 25, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.96 (Mar 24) to 5.48, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ipca Laboratories Ltd:
- Net Profit Margin: 8.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.15% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.61% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.69
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 35.8 (Industry average Stock P/E: 42.96)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 48, Kandivli Industrial Estate, Kandivli (West), Mumbai Maharashtra 400067 | ipca@pca.com http://www.ipca.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Premchand Godha | Executive Chairman |
| Mr. Ajit Kumar Jain | Managing Director & CFO |
| Mr. Pranay Godha | Managing Director & CEO |
| Mr. Prashant Godha | Executive Director |
| Dr.(Ms.) Swati Patankar | Independent Director |
| Dr. Narendra Mairpady | Independent Director |
| Mr. Vivek Shiralkar | Independent Director |
| Mr. Kamal Kishore Seth | Independent Director |
FAQ
What is the intrinsic value of Ipca Laboratories Ltd?
Ipca Laboratories Ltd's intrinsic value (as of 28 November 2025) is 1077.23 which is 22.83% lower the current market price of 1,396.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 35,466 Cr. market cap, FY2025-2026 high/low of 1,758/1,168, reserves of ₹6,923 Cr, and liabilities of 11,744 Cr.
What is the Market Cap of Ipca Laboratories Ltd?
The Market Cap of Ipca Laboratories Ltd is 35,466 Cr..
What is the current Stock Price of Ipca Laboratories Ltd as on 28 November 2025?
The current stock price of Ipca Laboratories Ltd as on 28 November 2025 is 1,396.
What is the High / Low of Ipca Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ipca Laboratories Ltd stocks is 1,758/1,168.
What is the Stock P/E of Ipca Laboratories Ltd?
The Stock P/E of Ipca Laboratories Ltd is 35.8.
What is the Book Value of Ipca Laboratories Ltd?
The Book Value of Ipca Laboratories Ltd is 293.
What is the Dividend Yield of Ipca Laboratories Ltd?
The Dividend Yield of Ipca Laboratories Ltd is 0.29 %.
What is the ROCE of Ipca Laboratories Ltd?
The ROCE of Ipca Laboratories Ltd is 14.7 %.
What is the ROE of Ipca Laboratories Ltd?
The ROE of Ipca Laboratories Ltd is 12.8 %.
What is the Face Value of Ipca Laboratories Ltd?
The Face Value of Ipca Laboratories Ltd is 1.00.